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Sweet syndrome (SS) (Acute Febrile Neutrophilic Dermatosis) has been reported in association with autoimmune phenomena
including relapsing polychondritis, drug-induced lupus, and the development of antineutrophil cytoplasmic antibodies (ANCAs).
However, a combination of these autoimmune features has not been reported. Herein, we report a case of drug-induced bullous SS
with ocular and mucosal involvement, glomerulonephritis, and multiple autoimmune features including clinical polychondritis
with antitype II collagen antibodies, ANCAs, antinuclear (HEp-2), and antihistone antibodies in a patient on hydralazine and
carbamazepine.
1.Introduction
Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)
is characterized by rapid onset of fever, leukocytosis, and
painful erythematous edematous papules, plaques, and
nodules. Etiologies include infections, particularly from
upper respiratory or gastrointestinal sources; inﬂammatory
and autoimmune diseases; pregnancy; malignancy; drug;
and idiopathic. Rare clinical manifestations include bullous
lesions, oral involvement, glomerulonephritis, myositis, and
ocular manifestations including conjunctivitis, episcleritis,
and iridocyclitis [1–3]. Sweet syndrome (SS) has been
associatedwithautoimmunephenomenaincludingrelapsing
polychondritis, drug-induced lupus, and development of
antineutrophil cytoplasmic antibodies (ANCAs). However,
a combination of all these features has not been reported.
Herein, we report such a patient.
2.CaseReport
An 86-year-old female with bipolar disorder was admitted
with anxiety, insomnia, fatigue, and acute renal failure.
Although lithium levels were normal, lithium had been
discontinued and replaced with carbamazepine 100mg daily
2 days prior to admission. She was also taking hydralazine
100mg three times daily for hypertension for 2 years with no
dosage change in 8 months. On hospital day 8, she developed
feverandconjunctivitisfollowedbyoralerosionsandpainful
lesions on her nose, ears, back, and ﬁngers.
On examination, she appeared acutely ill and was febrile
(38.4
◦C). Bilateral conjunctivitis with exudative discharge
and periorbital edema was noted. Tense vesicles and bullae
with surrounding erythema were noted on her scalp, nose,
and back. The skin overlying the cartilaginous portions of
both ears was erythematous and edematous with focal bul-
lous change. The noncartilaginous lobes appeared normal.
Erosions were noted on the hard palate and gingival mucosa
(Figure 1). Tender hemorrhagic bullae were prominent on
distal and lateral ﬁngers (Figure 2).
Laboratory testing revealed elevated C-reactive protein
at 14mg/dl (normal = 0t o1m g / d L )a n de r y t h r o c y t es e d i -
mentationrateof72mm/hour(normal =0to17mm/hour).
Her white blood cell count was normal at 5.5/mm3 (normal
= 4.1 to 10.9/mm3) and hemoglobin was low at 9.7gm/dL2 Autoimmune Diseases
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Figure 1: (a) Drug-induced Sweet Syndrome demonstrating tense vesicles and bullae with surrounding erythema over nose. (b) Tense
inﬂammatory vesicles and bullae over central back. (c) Hemorrhagic bullae of distal ﬁnger pads and lateral ﬁngers. (d) Erythema, edema,
and focal bullous change overlying the cartilaginous portions of both ears. The non-cartilagenous lobes demonstrated no inﬂammatory
changes. (e) Bullous lesions and erosions on the hard palate.
Table 1: Drugs associated with Sweet’s Syndrome.
Abacavir
All-trans retinoic acid
Bortezomib
Carbamazapine
Celecoxib
Clozapine
Diclofenac
Diazepam
Furosemide
Granulocyte colony-stimulating factor
Hydralazine
Imatinib
Lenalidomide
Minocycline
Nitrofurantoin
Norﬂoxacin
Oﬂoxacin
Oral Contraceptives
Pegﬁlgastrin
Propylthiouracil
Quinupristin/Dalfopristin
Trimethoprim-sulfamethoxazole
Figure 2: 3mm punch biopsy-upper back skin with focal subepi-
dermal vesicles with neutrophilic microabscesses, perivascular and
interstitial neutrophilic dermal inﬁltrate with leukocytoclasis 10x.
(normal = 11.7 to 15.5gm/dL). Serum creatinine was
2.1mg/dl (normal = 11.7 to 15.5gm/dL). Serum creatinine
was 2.1mg/d and urinalysis demonstrated a new proteinuria
(30mg/dl) with hematuria (51 to 100 red blood cells/hp).
Further labs showed positive AntiNuclear Antibody (HEp-2)
with homogenous pattern of 1:640 (normal < 1:160). Anti-
histone antibodies were elevated at 3.7 units (positive >1.5
units, Mayo Medical Laboratories). Perinuclear antineu-
trophil cytoplasmic antibodies (pANCAs) were positive to
myeloperoxidase and proteinase 3 at 200 units/ml (normal
= 0t o9u n i t s / m l )a n d4 8 . 5u n i t s / m l( n o r m a l= 0t oAutoimmune Diseases 3
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Figure 3: Clearing of aﬀected areas 3 weeks following discharge on tapering dose of prednisone.
3.5 units/ml), respectively. Anti-double-stranded DNA, anti-
Smith, anti-RNP, SSA, SSB, SCL-70, or JO-1 antibodies were
notdetected,andcomplementlevelswerenormal.Bloodand
urine cultures were negative. Serum protein electrophoresis
showed acute phase reaction pattern.
Three-millimeter punch biopsies from the back and
ﬁnger demonstrated focal subepidermal vesicles with neu-
trophilic microabscesses, perivascular and interstitial neu-
trophilic dermal inﬁltrate, and leukocytoclasis without vas-
culitis (Figure 2). Perilesional direct immunoﬂourescence
(DIF) was negative. The patient declined ear cartilage
biopsy, but anti-type II collagen antibodies were positive
(47.6EU/ml; normal <20EU/ml; Mayo Medical Laborato-
ries).
Drug-induced SS was suspected. Both carbamazepine
and hydralazine were discontinued, and the patient was
started on oral prednisone 60mg daily. The patient declined
renal biopsy. Her renal function, skin lesions, and mucosal
lesions improved on prednisone, and she was discharged
on a tapering dose. Skin lesions were resolved three weeks
following discharge (Figure 3)H e rM P Oa n dP R - 3t i t e r s
(57.7units/ml and 11.1units/ml, respectively) also decreased
as her symptoms improved. The patient died of unknown
causes 2 months following discharge, still on a tapering
prednisone dose.
3. Discussion
The criteria for drug-induced Sweet Syndrome (SS) include
the following [4]: an abrupt onset of painful erythematous
plaques or nodules; histopathologic evidence of a dense
neutrophilic inﬁltrate without evidence of leukocytoclastic
vasculitis; pyrexia > 38
◦C; temporal relationship between
drug ingestion and clinical presentation, or recurrence after
drug rechallenge; temporal relationship of resolution of
lesions after drug withdrawal or treatment with systemic
corticosteroids. In a review of 49 cases of drug-induced
SS, leukocytosis was only documented in 11 cases [5].
Therefore, a normal white blood cell count should not rule
out this diagnosis. Drug-induced SS occurs more often in
women. The average time to onset of clinical symptoms after
beginning drug therapy is 7.5 days [4, 5].
The pathophysiology of drug-induced SS is not clearly
understood, and additional associated autoimmune features
have been reported. Carbamazepine is known to cause drug-
induced SS and drug-induced systemic lupus erythematosus
(SLE) [6–8]. While carbamazepine is the most likely trigger,
as onset of this therapy occurred 10 days prior to the
development of our patient’s cutaneous disease and fever,
hydralazine was also considered, since hydralazine-induced
SLEmayoccur6monthsto6yearsafterstartingthedrug[9–
12]. Since both drugs reportedly induce drug-induced SLE,
a bullous variant of this disease must be considered in our
patient.
In reports of drug-induced bullous SLE, histopathologic
examination demonstrated an interstitial neutrophilic inﬁl-
trate with subepidermal blister formation, interface change,
and a positive DIF showing linear deposition of IgA and
IgG at the basement membrane zone [13, 14]. Our patient
hadantihistoneantibodieswhichmayoccurindrug-induced
SLE [7], but the biopsy and clinical features best supports
SS.Fever,oralerosions,andglomerulonephritishaveallbeen
reported in SS, butrenalmanifestations rarely occurin drug-
induced SLE [8]. In this case, it is diﬃcult to conclude that
the patient’s glomerulonephritis was directly related, as she
was admitted with renal failure. Medications may induce SS
with autoantibody proﬁles that mimic drug-induced SLE,
but the skin eruptions lack characteristic histologic features
of cutaneous lupus [12].
Sweet Syndrome has also been associated with relaps-
ing polychondritis [15–22], usually in association with
an underlying hematologic malignancy, dyscrasia, or solid
malignancy. Our patient’s clinical presentation of auricular
inﬂammation that spared the non-cartilaginous lobes with
anti-type II collagen antibodies supports the diagnosis of
drug-induced autoimmune polychondritis.
CytoplasmicANCA(c-ANCA)canoccurinpatientswith
SS [23]. Multiple cases of drug-induced SS in association
with positive p-ANCA antibodies have also been reported
[24,25].Thepresenceofp-ANCAwithanti-MPOantibodies4 Autoimmune Diseases
appears to occur more commonly in drug-induced cases
of SS [26]. ANCA may contribute to the pathogenesis of
neutrophilic dermatoses [25].
4. Conclusion
Drug-induced SS is a unique dermatosis which may have
unusual clinical and laboratory associations. Either carba-
mazepine or hydralazine may have incited this severe reac-
tion. This case demonstrates unusual clinical features and
multiple associated drug-induced autoimmune phenomena.
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